Precigenetics Aims for Real-Time Epigenome Interaction with Aging Drugs, Promising New Era in Precision Medicine

Philadelphia, PA – Precigenetics, a biotechnology company founded in 2024, is pioneering a novel approach to drug discovery, focusing on real-time observation of epigenome interactions with potential aging therapeutics. The company recently announced its ambitious vision on social media, stating, "imagine seeing your epigenome interact with your aging drug in real time – that's our promise at Precigenetics - soon, you will be able to do this." This initiative signals a significant shift towards more dynamic and personalized medicine in the longevity and disease prevention sectors.

The company's core technology, termed "sensor intelligence," integrates advanced biosensors, quantum optics, and artificial intelligence to enable real-time chemical imaging of live cells. This innovative platform allows for the simultaneous capture and analysis of epigenetic dynamics within the cell's nucleus as drugs interact with biological systems. This capability is designed to overcome the limitations of traditional drug discovery, which often relies on static snapshots and indirect evidence, aiming to provide unprecedented clarity into drug-cell interactions.

Epigenetics, the study of heritable changes in gene expression that do not involve alterations to the DNA sequence, plays a crucial role in aging and disease progression. Scientists have long sought to understand how environmental factors and biological processes influence the epigenome, leading to the development of "epigenetic clocks" that measure biological age. Precigenetics' approach directly addresses this by visualizing these intricate changes as they occur, potentially accelerating the identification of effective compounds for age-related conditions and other complex diseases.

This real-time visualization technology could revolutionize the development of aging drugs and therapies for conditions like cancer, where epigenetic dysregulation is a known factor. By providing immediate feedback on how a drug influences the epigenome, Precigenetics aims to significantly reduce the time and cost associated with drug development, offering a more precise and predictive method for identifying therapeutic candidates. The company emphasizes that its initial applications will focus on precision epigenetics in oncology and aging.

It is important to note that Precigenetics is a distinct entity from Precigen, a publicly traded biotechnology company specializing in gene and cell therapies. Precigenetics, a privately held firm, was established in 2024 and is specifically dedicated to advancing precision medicine through its unique real-time epigenetics platform. The company has recently expanded its team with key hires in biology and hardware innovation, indicating active development of its proprietary technology.